BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33613700)

  • 1. Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program.
    Bertho M; Fraisse J; Patsouris A; Cottu P; Arnedos M; Pérol D; Jaffré A; Goncalves A; Lebitasy MP; D'Hondt V; Dalenc F; Ferrero JM; Levy C; Dabakuyo S; Rouzier R; Penault-Llorca F; Uwer L; Eymard JC; Breton M; Chevrot M; Thureau S; Petit T; Simon G; Frénel JS
    Ther Adv Med Oncol; 2021; 13():1758835920987657. PubMed ID: 33613700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort study.
    Dalenc F; Lusque A; De La Motte Rouge T; Pistilli B; Brain E; Pasquier D; Debled M; Thery JC; Gonçalves A; Desmoulins I; Levy C; Uwer L; Ferrero JM; Eymard JC; Mouret-Reynier MA; Patsouris A; Frenel JS; Petit T; Chevrot M; Bachelot T; Guiu S
    Eur J Cancer; 2022 Mar; 164():70-79. PubMed ID: 35176614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016.
    Deluche E; Antoine A; Bachelot T; Lardy-Cleaud A; Dieras V; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Courtinard C; Perol D; Robain M; Delaloge S
    Eur J Cancer; 2020 Apr; 129():60-70. PubMed ID: 32135312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort.
    Gobbini E; Ezzalfani M; Dieras V; Bachelot T; Brain E; Debled M; Jacot W; Mouret-Reynier MA; Goncalves A; Dalenc F; Patsouris A; Ferrero JM; Levy C; Lorgis V; Vanlemmens L; Lefeuvre-Plesse C; Mathoulin-Pelissier S; Petit T; Uwer L; Jouannaud C; Leheurteur M; Lacroix-Triki M; Cleaud AL; Robain M; Courtinard C; Cailliot C; Perol D; Delaloge S
    Eur J Cancer; 2018 Jun; 96():17-24. PubMed ID: 29660596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008-2017 ESME cohort.
    Grinda T; Antoine A; Jacot W; Blaye C; Cottu PH; Diéras V; Dalenc F; Gonçalves A; Debled M; Patsouris A; Mouret-Reynier MA; Mailliez A; Clatot F; Levy C; Ferrero JM; Desmoulins I; Uwer L; Petit T; Jouannaud C; Lacroix-Triki M; Deluche E; Robain M; Courtinard C; Bachelot T; Brain E; Pérol D; Delaloge S
    ESMO Open; 2021 Jun; 6(3):100114. PubMed ID: 33895695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
    Galvin A; Courtinard C; Bouteiller F; Gourgou S; Dalenc F; Jacot W; Arnedos M; Bailleux C; Dieras V; Petit T; Emile G; Dubray-Longeras P; Frenel JS; Bachelot T; Mailliez A; Brain E; Desmoulins I; Massard V; Patsouris A; Goncalves A; Grinda T; Delaloge S; Bellera C
    Eur J Cancer; 2024 Jan; 196():113422. PubMed ID: 37977105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.
    Delaloge S; Pérol D; Courtinard C; Brain E; Asselain B; Bachelot T; Debled M; Dieras V; Campone M; Levy C; Jacot W; Lorgis V; Veyret C; Dalenc F; Ferrero JM; Uwer L; Kerbrat P; Goncalves A; Mouret-Reynier MA; Petit T; Jouannaud C; Vanlemmens L; Chenuc G; Guesmia T; Robain M; Cailliot C
    Ann Oncol; 2016 Sep; 27(9):1725-32. PubMed ID: 27436849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-World Impact of Adjuvant Anti-HER2 Treatment on Characteristics and Outcomes of Women With HER2-Positive Metastatic Breast Cancer in the ESME Program.
    Le Du F; Carton M; Bachelot T; Saghatchian M; Pistilli B; Brain E; Loirat D; Vanlemmens L; Vermeulin T; Emile G; Gonçalves A; Ung M; Robert M; Jaffre A; Desmoulins I; Jouannaud C; Uwer L; Marc Ferrero J; Mouret-Reynier MA; Jacot W; Chevrot M; Delaloge S; Diéras V
    Oncologist; 2023 Oct; 28(10):e867-e876. PubMed ID: 37589218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment and outcomes of older versus younger women with HER2-positive metastatic breast cancer in the real-world national ESME database.
    Annonay M; Gauquelin L; Geiss R; Ung M; Cristol-Dalstein L; Mouret-Reynier MA; Goncalves A; Abadie-Lacourtoisie S; Francois E; Perrin C; Le Fel J; Lorgis V; Servent V; Uwer L; Jouannaud C; Leheurteur M; Joly F; Campion L; Courtinard C; Villacroux O; Petit T; Soubeyran P; Terret C; Bellera C; Brain E; Delaloge S
    Breast; 2021 Dec; 60():138-146. PubMed ID: 34624756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.
    de Calbiac O; Lusque A; Mailliez A; Bachelot T; Uwer L; Mouret-Reynier MA; Emile G; Jouannaud C; Gonçalves A; Patsouris A; Diéras V; Leheurteur M; Petit T; Cottu P; Ferrero JM; D'Hondt V; Desmoulins I; Mourato-Ribeiro J; Martin AL; Frenel JS
    JAMA Netw Open; 2022 Sep; 5(9):e2231170. PubMed ID: 36107428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
    Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
    Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
    Cabel L; Carton M; Cheaib B; Pierga JY; Dalenc F; Mailliez A; Levy C; Jacot W; Debled M; Leheurteur M; Desmoulins I; Lefeuvre C; Gonçalves A; Uwer L; Ferrero JM; Eymard JC; Petit T; Mouret-Reynier MA; Perrocheau G; Piot I; Pérol D; Simon G; Lerebours F
    Breast Cancer Res Treat; 2019 Jan; 173(2):397-406. PubMed ID: 30357526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Endocrine Therapy for HR+/ERBB2+ Metastatic Breast Cancer With Survival Outcomes.
    Carausu M; Carton M; Diéras V; Petit T; Guiu S; Gonçalves A; Augereau P; Ferrero JM; Levy C; Ung M; Desmoulins I; Debled M; Bachelot T; Pistilli B; Frenel JS; Mailliez A; Chevrot M; Cabel L
    JAMA Netw Open; 2022 Dec; 5(12):e2247154. PubMed ID: 36520434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management and outcome of male metastatic breast cancer in the national multicenter observational research program Epidemiological Strategy and Medical Economics (ESME).
    Sirieix J; Fraisse J; Mathoulin-Pelissier S; Leheurteur M; Vanlemmens L; Jouannaud C; Diéras V; Lévy C; Ung M; Mouret-Reynier MA; Petit T; Coudert B; Brain E; Pistilli B; Ferrero JM; Goncalves A; Uwer L; Patsouris A; Tredan O; Courtinard C; Gourgou S; Frénel JS
    Ther Adv Med Oncol; 2020; 12():1758835920980548. PubMed ID: 33488779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between progression-free survival and overall survival in women receiving first-line treatment for metastatic breast cancer: evidence from the ESME real-world database.
    Courtinard C; Gourgou S; Jacot W; Carton M; Guérin O; Vacher L; Bertaut A; Le Deley MC; Pérol D; Marino P; Levy C; Uwer L; Perrocheau G; Schiappa R; Bachelot F; Parent D; Breton M; Petit T; Filleron T; Loeb A; Pélissier SM; Robain M; Delaloge S; Bellera C
    BMC Med; 2023 Mar; 21(1):87. PubMed ID: 36882736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic inflammatory breast cancer: survival outcomes and prognostic factors in the national, multicentric, and real-life French cohort (ESME).
    Dano D; Lardy-Cleaud A; Monneur A; Quenel-Tueux N; Levy C; Mouret-Reynier MA; Coudert B; Mailliez A; Ferrero JM; Guiu S; Campone M; de La Motte Rouge T; Petit T; Pistilli B; Dalenc F; Simon G; Lerebours F; Chabaud S; Bertucci F; Gonçalves A
    ESMO Open; 2021 Aug; 6(4):100220. PubMed ID: 34303929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study.
    Le Saux O; Lardy-Cleaud A; Frank S; Debled M; Cottu PH; Pistilli B; Vanlemmens L; Leheurteur M; Lévy C; Laborde L; Uwer L; D'hondt V; Berchery D; Lorgis V; Ferrero JM; Perrocheau G; Courtinard C; Mouret-Reynier MA; Velten M; Breton M; Parent D; Chabaud S; Robain M; Bachelot T
    Eur J Cancer; 2019 Sep; 118():131-141. PubMed ID: 31330488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world clinical and survival outcomes of patients with early relapsed triple-negative breast cancer from the ESME national cohort.
    Grinda T; Antoine A; Jacot W; Cottu PH; de la Motte Rouge T; Frenel JS; Mailliez A; Dalenc F; Goncalves A; Clatot F; Mouret Reynier MA; Levy C; Ferrero JM; Desmoulins I; Uwer L; Petit T; Jouannaud C; Arnedos M; Chevrot M; Courtinard C; Tredan O; Brain E; Pérol D; Pistilli B; Delaloge S
    Eur J Cancer; 2023 Aug; 189():112935. PubMed ID: 37385070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiological characteristics, clinical outcomes and management patterns of metastatic breast cancer patients in routine clinical care settings of Greece: Results from the EMERGE multicenter retrospective chart review study.
    Kotsakis A; Ardavanis A; Koumakis G; Samantas E; Psyrri A; Papadimitriou C
    BMC Cancer; 2019 Jan; 19(1):88. PubMed ID: 30658600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
    Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
    Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.